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n November, the cancer charity Cancer Research UK announced its research strategy for the next 5 years. Included in it are goals to increase research on the early diagnosis of cancer; invest more in research on radiotherapy and surgery; and devote more research to cancers of the lung, pancreas, and esophagus. But for some researchers, the strategy is notable for what it doesn't include: Cancer Research UK has decided to discontinue funding research in several areas it has long supported, including psychosocial oncology.
The decision has "created seismic shockwaves" throughout the psychosocial oncology research community, said Lesley Fallowfi eld, Ph.D., director of the Cancer Research UK Sussex Psychosocial Oncology Group at the University of Sussex. At the same time, it means that she and her colleagues have to start looking for new funding in an uncertain economy. "With the current economic gloom and doom, this is not a good time to be looking for other funders," Fallowfi eld said.
Broadly defi ned, psychosocial oncology investigates the psychological, behavioral, and social aspects of cancer. Cancer Research UK will continue to support all three programs until their grants run out, which is in 2011 for Fallowfi eld and 2012 for Sharpe and Velikova. Their program grants range from about £1.7 million to about £5 million over 5 years, "a mere blip" -less than 1% -of the organization's total research budget, Fallowfi eld said.
Cancer Research UK spent £333 million on research in fi scal year 2007 -2008 , and in 2007 the group funded about 46% of all cancer research in the UK, according to the National Cancer Research Institute (NCRI). The charity says it will continue to spend about £300 million a year for the foreseeable future. However, it is discontinuing research programs in palliative care, end-of-life care, survivorship, living with cancer, depression, quality of life, and complementary therapies -in addition to psychosocial oncology. It has also axed its clinical research training fellowship in psychosocial oncology.
The announcement has encountered criticism in the UK and elsewhere. Cancer Research UK's steady investment in psychosocial oncology over the years has produced quality, high-impact research, said Neil Aaronson, Ph.D., head of the Division of Psychosocial Research and Epidemiology at The Netherlands Cancer Institute. "The psychosocial oncology research community in the UK has a very strong reputation scientifi cally both in the UK, Europe, as well as the U.S. -all those groups published important work in their areas," Aaronson said. "It seems incomprehensible to me to have a new policy where you would be strategically shutting down very productive research groups."
A New Focus
But Cancer Research UK says that the new strategy brings the charity's research goals in line with its mission to reduce the number of deaths from cancer. "All of the work we fund is directed to that aim," said Cancer Research UK chief executive Harpal Kumar. The strategy resulted from a series of consultations with leaders in the fi eld and the research community, as well as within its own steering committees.
"We have identifi ed for ourselves a niche in understanding the disease and in the middle of the 'basic-to-clinical ' research spectrum," says a statement accompanying the online version of the research strategy. "We will therefore focus our research on the understanding of cancer, through to the treatment of cancer." Kumar further explained: "What we have to recognize is that no one organization can cover the entire fi eld of research activity. We are best placed to do research in those areas that are going to reduce mortality from cancer. Other organizations are better placed to think about issues, such as end-of-life care and so on. It's about working as a partnership, with each partner focusing on the areas that they're best able to contribute to." Kumar said he is talking with other organizations and encouraging them to take up funding research in psychosocial oncology. "We took the view that the whole fi eld of psychosocial oncology was something that needed more investment in the future … but it wasn't an area we felt we could invest more in, given everything else we're trying to do. We've been working very hard to fi nd a managed transition for this work, and I'm very optimistic that that will be possible," Kumar said. "That's what we've committed to all along." He noted that, in March, the charity Marie Curie Cancer Care announced that it would shift its research priorities -away from basic cancer research to research on end-of-life care.
The NCRI, which represents 21 organizations that fund cancer research in the UK, will also play a role in trying to fi nd new funders for psychosocial research in cancer. The organization has agreed to conduct a review of psychosocial oncology research to identify the research priorities and potential funders. National cancer director Mike Richards, M.D., will lead that review. "Psychosocial research … is extremely important, and I am very keen to see it fl ourish in this country," Richards said. "I am confi dent that a number of partners will come forward, but I think we need to do the planning jointly so we get the maximum benefi t."
Program Support
But researchers say that the loss of Cancer Research UK's programmatic funding may doom such efforts. Fallowfi eld has started to explore options with other funders but worries that it will be hard to fi nd funders who can support programs as a whole, providing the infrastructure to do a variety of studies.
"The diffi culty is that most project grants … are given to us predicated on the assumption that we do have core funding for a program grant," Fallowfi eld said. "So the likelihood of being able to get $50,000 here, $100,000 there, to do smaller albeit important projects becomes more diffi cult."
Psychosocial researchers also worry that the fi eld will lose its "high quality and a high profi le, which you can only really do when you get high-quality programmatic funding," Sharpe said. "I think the risk is that the fi eld will fall back to low-level research in low-level journals, which will have no impact."
The discontinuation of funding is "particularly disappointing at a point in time in the development of the fi eld where people are going from observational studies and epidemiologic work to intervention work Leslie Fallowfi eld, Ph.D.
that they're having trouble getting funded," Aaronson said. He added that it's not just the current generation of psychosocial researchers who will be affected: "My concern … was that not only would [Cancer Research UK] be affecting the current generation of scientists, but there would be problems in terms of career opportunities for young scientists who might be considering going into that area of research," he said.
Another concern is that funders who might be capable of supporting psychosocial oncology programs aren't disease specifi c, so researchers will be competing against research proposals that may have a broader focus. "I'm a researcher who does clinical trials of nondrug treatments to improve patients' quality of life," Sharpe said. "If we can't carry on that work [in cancer], if there isn't funding, we're not going to give up; we'll do it somewhere else."
Velikova and Fallowfi eld noted that they, too, will probably move oneither to another research area or out of research altogether -if they can't fi nd a funder willing to invest in their research.
Those in the fi eld will be watching to see what funders emerge and what comes of the NCRI review. The fi eld has Richards' support: "Good research in this area will lead to, at the very least, better quality of life, and it may at times lead to longer quantity of life," he said. "If you take the UK as a whole, we estimate there are around 2 million survivors of cancer. We clearly have a duty to optimize their quality of care and their quality of life."
